/PRNewswire/ The "Neuromodulation - Global Strategic Business Report" report has been added to ResearchAndMarkets.com s offering. Global Neuromodulation.
Using a novel deep brain stimulation (DBS) device capable of recording brain signals, researchers have identified a pattern of brain activity or "biomarker" related to clinical signs of recovery from treatment-resistant depression.
A multidisciplinary team of clinicians, engineers, and neuroscientists has identified a unique biomarker in the brain that indicates recovery from treatment-resistant depression, utilizing deep brain stimulation (DBS) and artificial intelligence. The discovery, which allows for real-time monitoring and tailoring of treatment, could revolutionize the approach to managing severe forms of depression.
Article: The Ka-Ching Ka-Ching of Clinical Depression - The Ka-Ching Ka-Ching of Depression is worth about $15.3 billion per year. The author laments having had depression for 20 years and being given nothing but meds. However, he is now seeking to fund raise for a DBS-implant operation for a permanent cure.